Share on

Global Leukemia Therapeutics Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Disease Condition, Diagnosis, Treatments, Drugs & Region - Industry Forecast (2023 to 2028)

Published: March, 2023
ID: 764
Pages: 175
Formats: report pdf report excel report power bi report ppt

Leukemia Therapeutics Market Size (2023 to 2028)

The global leukemia therapeutics market is expected to be worth USD 12.66 billion by 2028 and USD 8.04 billion in 2023, growing at a CAGR of 9.5% from 2023 to 2028.

Leukemia Therapeutics is a blood-forming tissue cancer that affects the blood components and bone marrow. When the bone marrow generates damaged lymphocytes, the generation of antibodies becomes defective, and the body's capacity to fight infections is lost. Leukemia is rising as a life-threatening concern around the globe, among other cancer forms. The leukemia therapeutics market includes a variety of therapies recommended by doctors for the treatment of leukemia. Leukemia is caused by various circumstances, including genetic mutations and a family history of the disease. Due to its radiographic abilities, Leukemia Therapeutics is an image scanner intensifier for intraoperative imaging in surgical, orthopedic, or emergency diagnostic operations.


The global leukemia therapeutics market is driven mainly due to an increasingly aging population, resulting in an increasing leukemia prevalence.

The disease occurrence is primarily seen in middle-aged people and senior citizens. With recent breakthroughs in this area by Research teams across the globe, the scope for treatments is widening. The global leukemia therapeutics market is further driven by the rising prevalence of cancers such as acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia, and chronic myeloid leukemia. In addition, the action of novel acceptable increase and launch of new drugs into existence is also driving the global leukemia therapeutics market. The market growth also influences older people who need special care and increased research and development of new cancer therapies. In some countries, the factors that accelerate market growth are increased research and development, many patients, and a rise in funds from the government.

Introduction to the book of therapies in a well-organized and competent way and with fewer side-effects, metabolic inhibitors, and pipeline products waiting for approval are expected to favor the growth of the global leukemia therapeutics market. Nowadays, bone marrow transplant and stem cell therapy are the upcoming trends in the leukemia therapeutics market, expected to boom the market. However, limited treatment options and the availability of the generic form of drugs restrain the growth of the global leukemia therapeutics market. Furthermore, high unmet needs for diagnosis are also hampering the market growth. In addition, the treatment cost is high, and preventing the success or harmful effects of the treatment further controls the market development.

The breakthrough therapy designations and increase in the amount or extent of approvals granted by regulatory bodies such as the FDA provide lucrative opportunities for the drug innovators in the market to grow the global market. Bringing new ideas into the market and safer therapies could develop an opportunity to develop the worldwide leukemia therapy market. Upcoming new idealistic therapeutics create an opportunity for the growth of the leukemia therapeutics business. The government has taken charge, which is approved. The forthcoming new ideas for drug treatment are estimated to produce opportunities for the leading global leukemia therapeutics market. The quantitative analysis of the market and estimations enable the key stakeholders to invest a massive amount in prevailing market opportunities. 


The restraints in the global leukemia therapeutics market are the lack of getting diagnosed early and no awareness among the people. The drug lifecycle roadmap is also a significant challenge that is redefining for drug innovators. Additionally, high treatment costs and drug costs hinder the growth of the global leukemia therapeutics market.

Impact of COVID-19 on the global leukemia therapeutics market:

The COVID-19 pandemic has had a positive and negative impact on the healthcare sector. Various governments worldwide have imposed strict lockdowns to control the spread of the coronavirus, resulting in an imbalance in the demand and supply of pharmaceutical products in the healthcare industry. The majority of the companies have manufacturing facilities in developed countries such as the United States, the United Kingdom, and Germany, where the pandemic has had a significant effect on company profits for various healthcare products. Furthermore, as the number of non-COVID-19 patients in hospitals declined, it decreased the number of procedures and prescriptions for disease treatments. Besides that, according to the U.K. Coronavirus Cancer Monitoring Project (UKCCMP), blood cancer patients, particularly those with leukemia, multiple myeloma, and lymphoma, are at a greater risk of acquiring the COVID-19 virus, increasing the demand for leukemia therapeutics. As a result of these and other similar results, demand for leukemia therapeutics has increased during the COVID-19 pandemic, with market players reporting increased sales.




Market Size Available

2022 to 2028

Base Year


Forecast Period

2023 to 2028

Segments Covered

By Disease Condition, Diagnosis, Treatments, Drugs and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia-Pacific, Latin America, Middle East & Africa


This research report on the global leukemia therapeutics market has been segmented and sub-segmented based on the disease condition, diagnosis, treatments, drugs, and region.

Leukemia Therapeutics Market - By Disease Condition:

  • Chronic Lymphatic Leukemia           
  • Acute Lymphatic Leukemia              
  • Chronic Myeloid Leukemia               
  • Acute Myeloid Leukemia  

By disease condition, chronic myeloid leukemia dominated the overall therapeutic market owing to the high prevalence rate. High prevalence rates, high drug therapy rates, and fast uptake of second-generation tyrosine kinase inhibitors are major factors for the segment to grow tremendously.

Leukemia Therapeutics Market - By Diagnosis:

  • CT scan     
  • Biopsy       
  • MRI            

Based on the diagnosis, the MRI segment is ruling with the dominant shares of the market. MRI is a better choice than x-rays or CT scans when doctors need a view of soft tissues. MRIs can provide clearer images of organs and soft tissues, such as torn ligaments and herniated discs, compared to CT images.

Leukemia Therapeutics Market - By Treatments:

  • Chemotherapy      
  • Radiation therapy
  • Immunotherapy   
  • Surgery     
  • Targeted Therapy
  • Bone marrow transplant   
  • Stem Cell Therapy

Stem cell therapy and bone marrow transplant segments are emerging trends in the leukemia therapeutics market based on treatments. In addition, chemotherapy is another promising segment due to its ability to kill cancerous cells or inhibit their proliferation while maintaining a normal lymphocyte level in chemotherapy.

Leukemia Therapeutics Market - By Drugs:

  • Gleevec    
  • Sapacitabine           
  • GA101       
  • Vasaroxine              
  • Tosedosat               

Based on drugs, the Gleevec segment was one of the significant market growth contributors.

Leukemia Therapeutics Market – By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

Geographically, North America holds the largest share of the global leukemia therapeutics market, followed by Europe. Factors such as the rising prevalence of cervical cancer, growing awareness of cervical cancer screening programs, and government support drive the growth of the Leukemia therapeutics market in the North American region. On the other hand, the European market is predicted to be the second-most promising regional market in the global market. The rapid growth of these two areas can be attributed to consumers' increasing awareness of effective therapeutics' availability in the coming years. Furthermore, technological advances and favorable government policies and initiatives are expected to boost the market for leukemia therapeutics in North America and Europe in the near future.

Asia Pacific market is growing rapidly due to the rising consumer market, increasing the aging population, and raising awareness for healthcare among the population in the region's developing nations. Furthermore, developing healthcare infrastructure in emerging economies offers promising growth opportunities for Asia Pacific market players. The rising contribution from China, India, and Japan and growing investments in research and development are expected to boost the Asia Pacific leukemia therapeutics market in the coming years. Additionally, rising consumer disposable income and the growing prevalence of leukemia are expected to drive market growth over the forecast period.


Some of the prominent companies dominating the global leukemia therapeutics market profiled in this report are F. Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited, Novartis International AG, Bristol-Myers Squibb, Eisai Co. Ltd, Biogen Idec, ERYtech Pharma, Celgene Corporation, Genmab A/S, Cephalon Inc., Clavis Pharma, and Pfizer Inc.


  • Blinatumomab, in September 2018, received approval for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia in Japan. 
  • The EU approved BLINCYTO (blinatumomab) in January 2019 for patients with Philadelphia chromosome-negative minimal residual disease, a definite B-cell precursor acute lymphoblastic leukemia. Also, BLINCYTO is the only therapy that the EU has approved for minimal residual disease treatment. 
  • Celgene Corporation made a deal in July 2017 to develop and commercialize Beigenes investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317, for patients suffering from solid tumors.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample